UCB 관리

관리 기준 확인 4/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Jean-Christophe Tellier

최고 경영자

€5.8m

총 보상

CEO 급여 비율	21.2%
CEO 임기	8.3yrs
CEO 소유권	n/a
경영진 평균 재임 기간	5.5yrs
이사회 평균 재임 기간	9yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Jean-Christophe Tellier 의 보수는 UCB 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Dec 31 2022	€6m	€1m	€420m
Jun 30 2022	n/a	n/a	€887m
Mar 31 2022	n/a	n/a	€971m
Dec 31 2021	€6m	€1m	€1b
Sep 30 2021	n/a	n/a	€996m
Jun 30 2021	n/a	n/a	€936m
Mar 31 2021	n/a	n/a	€834m
Dec 31 2020	€7m	€1m	€732m
Jun 30 2020	n/a	n/a	€743m
Mar 31 2020	n/a	n/a	€767m
Dec 31 2019	€87k	n/a	€790m
Jun 30 2019	n/a	n/a	€652m
Mar 31 2019	n/a	n/a	€722m
Dec 31 2018	€76k	n/a	€792m
Jun 30 2018	n/a	n/a	€872m
Mar 31 2018	n/a	n/a	€812m
Dec 31 2017	€76k	n/a	€752m
Sep 30 2017	n/a	n/a	€708m
Jun 30 2017	n/a	n/a	€664m
Mar 31 2017	n/a	n/a	€604m
Dec 31 2016	€5m	€987k	€543m

보상 대 시장: Jean-Christophe 의 총 보상 ($USD 6.33M )은 Swiss 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 4.72M ).

보상과 수익: Jean-Christophe 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Jean-Christophe Tellier (63 yo)

8.3yrs

테뉴어

€5,808,530

보상

Mr. Jean-Christophe Tellier has been the Chief Executive Officer and Executive Director of UCB SA since January 1, 2015 and April 24, 2014 respectively and also was an Interim Chief Financial Officer since...

리더십 팀

이름	위치	테뉴어	보상	소유권
Jean-Christophe Tellier	CEO & Executive Director	8.3yrs	€5.81m	데이터 없음
Sandrine Dufour	Executive VP & CFO & Chief Corporate Development	2.8yrs	데이터 없음	데이터 없음
Kirsten Lund-Jurgensen	Executive Vice President of Supply & Technology Solutions	3.6yrs	데이터 없음	데이터 없음
Dhavalkumar Patel	Executive VP & Chief Scientific Officer	5.5yrs	데이터 없음	데이터 없음
William Silbey	Executive VP & General Counsel	4.1yrs	데이터 없음	데이터 없음
Jean-Luc Fleurial	Executive VP & Chief Human Resources Officer	3.2yrs	데이터 없음	데이터 없음
Iris Low-Friedrich	Executive VP	15.1yrs	데이터 없음	데이터 없음
Emmanuel Caeymaex	Executive VP of Immunology Solutions & Head of US	8.2yrs	데이터 없음	데이터 없음
Charl van Zyl	Executive VP of Neurology Solutions & Head of EU/International	3.6yrs	데이터 없음	데이터 없음
Caroline Vancoillie	Chief Accounting Officer	10.1yrs	데이터 없음	데이터 없음
Antje Witte	Head of Investor Relations	13.3yrs	데이터 없음	데이터 없음
Gwendoline Ornigg	Head of Global Communication	no data	데이터 없음	데이터 없음

5.5yrs

평균 재임 기간

61yo

평균 연령

경험이 풍부한 관리: UNC 의 관리팀은 노련하고 경험 (평균 재직 기간 5.5 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Jean-Christophe Tellier	CEO & Executive Director	9yrs	€5.81m	데이터 없음
Gerhard Mayr	Honorary Chairman	no data	€70.00k	데이터 없음
Mark Eyskens	Honorary Chairman	18.3yrs	€15.50k	데이터 없음
Daniel Janssen	Honorary Deputy Chairman	no data	€28.50k	데이터 없음
Albrecht De Graeve	Director	13yrs	€86.00k	데이터 없음
Georges Jacobs Hagen	Honorary Chairman	no data	€30.00k	데이터 없음
Diégo du de Bergendal	Honorary Chairman	2yrs	€87.50k	데이터 없음
Karel Boone	Honorary Chairman	no data	€49.00k	데이터 없음
Jonathan Peacock	Independent Chair of the Board	2yrs	€157.17k	데이터 없음
Charles-Antoine Emmanuel Janssen	Director	11yrs	€108.50k	데이터 없음
Jonkheer van Rijckevorsel	Director	9yrs	€86.00k	데이터 없음
Fiona du Monceau	Vice-Chair of the Board	2yrs	€159.83k	데이터 없음

9.0yrs

평균 재임 기간

67yo

평균 연령

경험이 풍부한 이사회: UNC 의 이사회는 경험(평균 재직 기간 9 년)으로 간주됩니다.

UCB 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

UCB SA, Annual General Meeting, Apr 24, 2025

UCB Announces Resignation of Head of Neurology Solutions Charl Van Zyl

UCB SA, Annual General Meeting, Apr 27, 2023

UCB SA, Annual General Meeting, Apr 28, 2022

Recent updates

UCB SA Receives U.S. FDA Approval for Bimzelx (Bimekizumab-Bkzx) as the First Il-17A and Il-17F Inhibitor for Adults with Moderate-Severe Hidradenitis Suppurativa

Ucb Announces New Bimzelx (Bimekizumab-Bkzx) Data at Acr Convergence 2024

UCB Announces Head-To-Head Study Evaluating Bimekizumab (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic Arthritis

UCB Announces Late-Breaking Two-Year Data for BIMZELX (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024

UCB Announces New CIMZIA® Data for Women Living with Chronic Rheumatic Diseases Throughout Pregnancy, and for People Living with Ra and High Rheumatoid Factor Levels

UCB SA, Annual General Meeting, Apr 24, 2025

UCB Announces FDA Accepts Supplemental Biologics License Applications for Bimzelx

UCB Announces 48-Week Phase 3 Analyses of Pooled Phase 3 Data from the BE HEARD I and BE HEARD II Studies

UCB Presents New Data About the Real-World Experience of FINTEPLA® (Fenfluramine) and Rare Epilepsy Syndromes At 2023 American Epilepsy Society (AES) Annual Meeting

UCB SA Announces U.S. Availability of BIMZELX for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis

UCB to Present Post Hoc Analysis of the EXXELERATE Trial Evaluating the Efficacy of CIMZIA®? (Certolizumab Pegol) and Adalimumab in Patients with Rheumatoid Arthritis and High Rheumatoid Factor

UCB Presents Latest Data from Generalized Myasthenia Gravis Portfolio

UCB SA Announces Publication of NAYZILAM® (midazolam) Results in 'Epilepsy & Behavior' Examining the Impact of Dose on Return to Full Baseline Function (RTFBF) for People with Seizure Clusters

UCB Announces U.S. FDA Approves BIMZELX (Bimekizumab-Bkzx) for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis

UCB Announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the Treatment of Adults with Generalized Myasthenia Gravis

UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023

UCB Announces Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa

UCB SA to Report Fiscal Year 2023 Results on Feb 21, 2024

Ucb Announces That Rystiggo Is Commercially Available for the Treatment of Adult Patients in the U.S. with Generalized Myasthenia Gravis (Gmg) Who Are Anti-Acetylcholine Receptor (Achr) or Anti-Muscle-Specific Tyrosine Kinase (Musk) Antibody Positive

UCB Announces Resignation of Head of Neurology Solutions Charl Van Zyl

UCB Announces Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis

UCB SA to Report Fiscal Year 2022 Results on Feb 22, 2023

UCB Announces Rozanolixizumab BLA for the Treatment of Generalized Myasthenia Gravis Filed with U.S. FDA and Designated for Priority Review

UCB Announces Positive Phase 3 Studies for Bimekizumab in Hidradenitis Suppurativa

UCB SA to Present Data At the American Epilepsy Society 76Th Annual Meeting 2022 Supporting A Decades-Long Commitment to Transforming Epilepsy Care

UCB Announces the Publication of Long-Term Open-Label Extension (OLE) Study Results of FINTEPLA® (Fenfluramine) CIV in Epilepsia

UCB Announces U.S. FDA Acceptance of New Drug Application and EMA MAA Validation for Zilucoplan for the Treatment of Generalized Myasthenia Gravis in Adult Patients

UCB Announces the First Presentation of Long-Term, 52-Week Data from Three Phase 3 Studies Evaluating the Efficacy and Safety of Bimekizumab in Adults with Active Psoriatic Arthritis

UCB Announces New Three-Year Results from the BE BRIGHT Open-Label Extension Study

First half 2022 earnings released

Investor sentiment deteriorated over the past week

UCB, Announces New 24-Week Data from Two Phase 3 Studies, Be Mobile 1 and Be Mobile 2

UCB SA Announces First Detailed Data from Two Phase 3 Bimekizumab Studies in Psoriatic Arthritis to Be Presented At EULAR 2022

UCB SA, Annual General Meeting, Apr 27, 2023

UCB Presents Efficacy and Safety Results for Zilucoplan and Rozanolixizumab in Generalized Myasthenia Gravis

UCB Announces Jama Neurology Publishes Phase 3 Study Results on the Efficacy and Safety of Fintepla® (Fenfluramine) Oral Solution in Lennox-Gastaut Syndrome

UCB SA Announces Oral Solution Civ Approves for Treatment of Seizures Associated with Lennox-Gastaut Syndrome

UCB SA, Annual General Meeting, Apr 28, 2022

UCB Announces Positive Data in Myasthenia Gravis with Zilucoplan Phase 3 Study Results

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령